CONTEXT THERAPEUTICS INC (CNTX)
Health Care · NASDAQ
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer cells.
What CONTEXT THERAPEUTICS INC does
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing T cell engaging (TCE) bispecific antibodies for solid tumors. The company is advancing three lead programs: CTIM-76 (a CLDN6 x CD3 TCE), CT-95 (a Mesothelin x CD3 TCE), and CT-202 (a Nectin-4 x CD3 TCE), each designed to redirect T-cell-mediated lysis toward malignant cells expressing specific tumor antigens. The company retains worldwide development and commercialization rights to its product candidates and aims to build an innovative portfolio of TCE bispecific therapeutics for cancer patients with significant unmet medical needs.
Themes: ["Solid tumors / oncology"]
Fundamentals
- Price$0.59 as of 2026-07-09 close
- Market cap$55M as of 2026-07-10
- 1-year return-5.9% as of 2026-07-09 close
- ROE-60.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.78 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: The company's success depends on the ability of its preclinical studies and clinical trials to demonstrate safety and efficacy of CTIM-76, CT-95, CT-202, and future product candidates; failure to achieve positive clinical results could delay or prevent regulatory approval."]
Competitors & peers
- Genmab
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.